Once-weekly insulin icodec non-inferior to daily insulin glargine for patients with type 2 diabetes on basal-bolus regimens
1. At 26 weeks, the mean change in HbA1c was comparable between the weekly insulin icodec and daily glargine U100 groups. 2. There was no significant difference in serious adverse events or hypoglycemic episodes between treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: A basal-bolus insulin regimen is often required for glycemic control in
Source: 2minutemedicine.com